PetVivo Holdings Inc. to Trade on OTCQX Best Market
PetVivo Holdings (OTCQX: PETV) has announced its upgrade from the OTCQB Venture Market to the OTCQX Best Market, marking a significant milestone for the biomedical device company. The OTCQX Market, which currently hosts 625 securities out of approximately 12,000 OTC securities, is designed for established companies meeting high financial standards and corporate governance requirements.
The company specializes in innovative medical devices for horses and companion animals, featuring two key products: Spryng with OsteoCushion Technology, an intra-articular injectable device for joint pain management, and PrecisePRP, an off-the-shelf platelet-rich plasma product containing 4 billion platelets per vial for veterinary use.
[ "Upgrade to OTCQX Best Market demonstrates meeting higher financial standards and corporate governance requirements", "Enhanced visibility and liquidity for investors through OTCQX trading", "Innovative product portfolio with Spryng and PrecisePRP targeting the veterinary medical device market" ]PetVivo Holdings (OTCQX: PETV) ha annunciato la sua promozione dal mercato OTCQB Venture al OTCQX Best Market, segnando un traguardo importante per l'azienda di dispositivi biomedicali. Il mercato OTCQX, che attualmente ospita 625 titoli su circa 12.000 titoli OTC, è riservato a società consolidate che soddisfano elevati standard finanziari e requisiti di governance aziendale.
L'azienda è specializzata in dispositivi medici innovativi per cavalli e animali da compagnia, con due prodotti principali: Spryng con tecnologia OsteoCushion, un dispositivo iniettabile intra-articolare per la gestione del dolore articolare, e PrecisePRP, un prodotto pronto all'uso di plasma ricco di piastrine contenente 4 miliardi di piastrine per fiala, destinato all'uso veterinario.
- La promozione al mercato OTCQX Best Market dimostra il rispetto di standard finanziari e di governance aziendale più elevati
- Maggiore visibilità e liquidità per gli investitori grazie alla negoziazione su OTCQX
- Portafoglio prodotti innovativo con Spryng e PrecisePRP rivolto al mercato dei dispositivi medici veterinari
PetVivo Holdings (OTCQX: PETV) ha anunciado su ascenso del mercado OTCQB Venture al OTCQX Best Market, marcando un hito significativo para la empresa de dispositivos biomédicos. El mercado OTCQX, que actualmente alberga 625 valores de aproximadamente 12,000 valores OTC, está diseñado para compañías consolidadas que cumplen con altos estándares financieros y requisitos de gobernanza corporativa.
La compañía se especializa en dispositivos médicos innovadores para caballos y animales de compañía, con dos productos clave: Spryng con tecnología OsteoCushion, un dispositivo inyectable intraarticular para el manejo del dolor articular, y PrecisePRP, un producto listo para usar de plasma rico en plaquetas que contiene 4 mil millones de plaquetas por vial para uso veterinario.
- El ascenso al mercado OTCQX Best Market demuestra el cumplimiento de estándares financieros y de gobernanza corporativa más altos
- Mayor visibilidad y liquidez para los inversores a través del comercio en OTCQX
- Cartera de productos innovadora con Spryng y PrecisePRP dirigida al mercado de dispositivos médicos veterinarios
PetVivo Holdings (OTCQX: PETV)는 OTCQB 벤처 마켓에서 OTCQX 베스트 마켓으로의 승격을 발표하며, 생체의학 기기 회사로서 중요한 이정표를 세웠습니다. 현재 약 12,000개의 OTC 증권 중 625개 증권이 상장된 OTCQX 마켓은 높은 재무 기준과 기업 지배구조 요건을 충족하는 확립된 기업을 위한 시장입니다.
이 회사는 말과 반려동물을 위한 혁신적인 의료 기기를 전문으로 하며, 두 가지 주요 제품은 관절 통증 관리를 위한 관절 내 주사 기기인 OsteoCushion 기술이 적용된 Spryng과 수의학용으로 1 바이알당 40억 개의 혈소판을 포함한 즉시 사용 가능한 혈소판 풍부 혈장 제품인 PrecisePRP입니다.
- OTCQX 베스트 마켓으로의 승격은 더 높은 재무 기준과 기업 지배구조 요건 충족을 의미합니다
- OTCQX 거래를 통한 투자자 대상 가시성 및 유동성 향상
- 수의학 의료기기 시장을 겨냥한 Spryng 및 PrecisePRP의 혁신적인 제품 포트폴리오
PetVivo Holdings (OTCQX : PETV) a annoncé sa montée du marché OTCQB Venture au OTCQX Best Market, marquant une étape importante pour cette entreprise de dispositifs biomédicaux. Le marché OTCQX, qui regroupe actuellement 625 titres sur environ 12 000 titres OTC, est destiné aux entreprises établies répondant à des normes financières élevées et à des exigences de gouvernance d'entreprise strictes.
L'entreprise se spécialise dans les dispositifs médicaux innovants pour chevaux et animaux de compagnie, avec deux produits phares : Spryng avec la technologie OsteoCushion, un dispositif injectable intra-articulaire pour la gestion de la douleur articulaire, et PrecisePRP, un produit de plasma riche en plaquettes prêt à l'emploi contenant 4 milliards de plaquettes par flacon, destiné à un usage vétérinaire.
- La montée au OTCQX Best Market témoigne du respect de normes financières et de gouvernance d'entreprise plus strictes
- Visibilité et liquidité accrues pour les investisseurs grâce à la cotation sur OTCQX
- Portefeuille de produits innovants avec Spryng et PrecisePRP ciblant le marché des dispositifs médicaux vétérinaires
PetVivo Holdings (OTCQX: PETV) hat den Aufstieg vom OTCQB Venture Market zum OTCQX Best Market bekannt gegeben, was einen bedeutenden Meilenstein für das biomedizinische Geräteunternehmen darstellt. Der OTCQX-Markt, auf dem derzeit 625 Wertpapiere von etwa 12.000 OTC-Wertpapieren gelistet sind, richtet sich an etablierte Unternehmen, die hohe finanzielle Standards und Anforderungen an die Unternehmensführung erfüllen.
Das Unternehmen ist auf innovative medizinische Geräte für Pferde und Begleittiere spezialisiert und bietet zwei Hauptprodukte an: Spryng mit OsteoCushion-Technologie, ein intraartikuläres injizierbares Gerät zur Behandlung von Gelenkschmerzen, und PrecisePRP, ein gebrauchsfertiges plättchenreiches Plasma-Produkt mit 4 Milliarden Thrombozyten pro Fläschchen für die veterinärmedizinische Anwendung.
- Der Aufstieg zum OTCQX Best Market zeigt die Erfüllung höherer finanzieller Standards und Anforderungen an die Unternehmensführung
- Erhöhte Sichtbarkeit und Liquidität für Investoren durch den Handel an der OTCQX
- Innovatives Produktportfolio mit Spryng und PrecisePRP, das den Markt für veterinärmedizinische Geräte anspricht
- None.
- Moving from OTCQB to OTCQX still keeps the company in the over-the-counter market rather than major exchanges
Insights
PetVivo's upgrade to OTCQX from OTCQB signals improved financial standing and potential for greater investor visibility and liquidity.
PetVivo Holdings has achieved a significant market upgrade by qualifying for the OTCQX Best Market, moving up from the OTCQB Venture Market. This transition represents more than just a change in trading venue—it's a meaningful validation of the company's financial progress. The OTCQX is considerably more exclusive, hosting only 625 securities compared to approximately 12,000 securities across the broader OTC Markets Group.
To qualify for OTCQX listing, companies must satisfy stringent criteria including high financial standards, best practice corporate governance, and securities law compliance. This upgrade typically translates to several tangible benefits for shareholders: enhanced visibility among U.S. investors, improved liquidity potential, and broader market recognition.
The upgrade comes as PetVivo continues commercializing its innovative veterinary medical devices—Spryng with OsteoCushion Technology and PrecisePRP. The first product addresses joint mechanics and pain management in animals, while PrecisePRP offers veterinarians an off-the-shelf platelet-rich plasma solution that eliminates the need for blood draws or centrifugation—a key differentiator in the veterinary market.
This market upgrade positions PetVivo to potentially attract institutional investors who may have been restricted from trading OTCQB securities due to investment mandates. While not as prestigious as a national exchange listing (NASDAQ or NYSE), the OTCQX upgrade represents a stepping stone that could facilitate capital raising and strategic growth initiatives as the company scales its veterinary medical device business.
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, such as Spryng® with OsteoCushion® Technology and PrecisePRP®, today announced that the Company has qualified to trade on the OTCQX® Best Market. PetVivo Holdings Inc. upgraded to OTCQX from the OTCQB® Venture Market.
PetVivo Holdings Inc. begins trading today on OTCQX under the symbol “PETV.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
The OTCQX Market is designed for established, investor-focused U.S. and international companies. The OTCQX Market has 625 securities as of today, while the broader OTC Markets Group includes approximately 12,000 securities. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.
PetVivo’s signature product, SPRYNG with OsteoCushion Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PetVivo’s other innovative product, PrecisePRP, is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.
“Qualifying to trade on the OTCQX Best Market is a significant milestone for our Company,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “This upgrade reflects our continued commitment to transparency, strong corporate governance, and delivering long-term value to our shareholders. Trading on OTCQX will enhance our visibility within the investment community and provide greater liquidity and accessibility for investors as we continue to execute on our strategic growth initiatives.”
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/, https://www.petvivoanimalhealth.com/ and https://www.sprynghealth.com.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for equine and companion animals. The Company's strategy is to leverage human therapies for the treatment of equine and companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What does PetVivo's (PETV) upgrade to OTCQX Best Market mean for investors?
What are PetVivo's (PETV) main products in 2025?
How does PetVivo's PrecisePRP differ from other PRP products?
What conditions does PetVivo's Spryng technology treat in animals?
